Ann Rheum Dis Volume 66(Suppl 3); November 2007

Volume 66(Suppl 3); November 2007

Preface

Advances in targeted therapies IX

F C Breedveld, J R Kalden, J S Smolen

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii1. doi: 10.1136/ard.2007.079772

PMCID:: PMC2095283

Full Text PDF–53K

Supplement

Actin cytoskeleton dynamics linked to synovial fibroblast activation as a novel pathogenic principle in TNF‐driven arthritis

Y Vasilopoulos, V Gkretsi, M Armaka, V Aidinis, G Kollias

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii23–iii28. doi: 10.1136/ard.2007.079822

PMCID:: PMC2095291

Abstract Full Text PDF–628K

New therapies for sepsis: focus on the interleukin (IL)12 family member IL27

Markus F Neurath

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii29–iii31. doi: 10.1136/ard.2007.078337

PMCID:: PMC2095287

Abstract Full Text PDF–410K

Interpreting measurements of physical function in clinical trials

Michael M Ward

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii32–iii34. doi: 10.1136/ard.2007.079806

PMCID:: PMC2095285

Abstract Full Text PDF–93K

Thoughts on health economics in rheumatoid arthritis

Gisela Kobelt

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii35–iii39. doi: 10.1136/ard.2007.078964

PMCID:: PMC2095296

Abstract Full Text PDF–242K

Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean?

Tore K Kvien, Turid Heiberg, Kåre B Hagen

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii40–iii41. doi: 10.1136/ard.2007.079798

PMCID:: PMC2095292

Abstract Full Text PDF–76K

Joint remodelling in inflammatory disease

Georg Schett

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii42–iii44. doi: 10.1136/ard.2007.078972

PMCID:: PMC2095295

Abstract Full Text PDF–336K

Amplifying elements of arthritis and joint destruction

Wim B van den Berg, Peter L van Lent, Leo A B Joosten, Shahla Abdollahi‐Roodsaz, Marije I Koenders

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii45–iii48. doi: 10.1136/ard.2007.079830

PMCID:: PMC2095284

Abstract Full Text PDF–1.3M

Schnurri‐3 is an essential regulator of osteoblast function and adult bone mass

Dallas C Jones, Marc N Wein, Laurie H Glimcher

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii49–iii51. doi: 10.1136/ard.2007.078352

PMCID:: PMC2095286

Abstract Full Text PDF–85K

Thomas A Luger, Thomas Brzoska

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii52–iii55. doi: 10.1136/ard.2007.079780

PMCID:: PMC2095288

Abstract Full Text PDF–156K

Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility

M F Bakker, J W G Jacobs, S M M Verstappen, J W J Bijlsma

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii56–iii60. doi: 10.1136/ard.2007.078360

PMCID:: PMC2095293

Abstract Full Text PDF–154K

Disease activity assessment in SLE: do we have the right instruments?

Michelle Petri

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii61–iii64. doi: 10.1136/ard.2007.078477

PMCID:: PMC2095289

Abstract Full Text PDF–143K

Systemic lupus erythematosus: new molecular targets

José C Crispín, Vasileios C Kyttaris, Yuang‐Taung Juang, George C Tsokos

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii65–iii69. doi: 10.1136/ard.2007.078493

PMCID:: PMC2095294

Abstract Full Text PDF–200K

Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy

Elena Gonzalez‐Rey, Per Anderson, Mario Delgado

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii70–iii76. doi: 10.1136/ard.2007.078519

PMCID:: PMC2095290

Abstract Full Text PDF–410K

Update on toll‐like receptor‐directed therapies for human disease

Kevin Tse, Anthony A Horner

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii77–iii80. doi: 10.1136/ard.2007.078998

PMCID:: PMC2095280

Abstract Full Text PDF–121K

Could toll‐like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue

Sandra M Sacre, Stefan K Drexler, Evangelos Andreakos, Marc Feldmann, Fionula M Brennan, Brian M J Foxwell

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii81–iii86. doi: 10.1136/ard.2007.079012

PMCID:: PMC2095278

Abstract Full Text PDF–287K

Interplay between pathogenic Th17 and regulatory T cells

Mohamed Oukka

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii87–iii90. doi: 10.1136/ard.2007.078527

PMCID:: PMC2095282

Abstract Full Text PDF–409K

Regulatory T cells and toll‐like receptors: regulating the regulators

Roger Sutmuller, Anja Garritsen, Gosse J Adema

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii91–iii95. doi: 10.1136/ard.2007.078535

PMCID:: PMC2095279

Abstract Full Text PDF–152K

Consensus Statement

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, P L C M van Riel, R Fleischmann, M H Weisman, M E Weinblatt

Ann Rheum Dis. 2007 November; 66(Suppl 3): iii2–iii22. doi: 10.1136/ard.2007.081430

PMCID:: PMC2095281

Full Text PDF–388K

Articles from Annals of the Rheumatic Diseases are provided here courtesy of
BMJ Group

PMC Canada | Copyright | Disclaimer

PubMed Central Canada is a service of the Canadian Institutes of Health Research (CIHR) working in partnership with the National Research Council's Canada Institute for Scientific and Technical Information in cooperation with the National Center for Biotechnology Information at the U.S. National Library of Medicine(NCBI/NLM). It includes content provided to the PubMed Central International archive by participating publishers.